Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APACHE: Plasma Exchange With Albumin 5% in ACLF
NCT03702920Phase 3Terminated
- Sponsor
- Grifols
- Start
- Jun 2019
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of human albumin in acute-on-chronic liver failure (ACLF) (2 arms), sponsored by Grifols. Primary endpoint: Time to Death Without a Prior Liver Transplant at 90 days. Started Jun 2019; status: terminated.
02
Drugs
human albumin
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT03702920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702920.